Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro

Immunopharmacology

Volumn 41, Issue 3, 1999, Pages 227-234

  Gruber, Andreas ^a   Speth, Cornelia ^a   Lukasser Vogl, Elisabeth ^a   Zangerle, Robert ^a   Borg Von Zepelin, Margarete ^b   Dierich, Manfred P ^a   Würzner, Reinhard ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Candida albicans; HIV 1; Indinavir

Indexed keywords

ASPARTIC PROTEINASE; INDINAVIR; PROTEINASE;

AMINO ACID SEQUENCE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FUNGUS GROWTH; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRULENCE;

AMINO ACID SEQUENCE; ASPARTIC ENDOPEPTIDASES; CANDIDA ALBICANS; HIV PROTEASE; HIV PROTEASE INHIBITORS; INDINAVIR; MOLECULAR SEQUENCE DATA; VIRULENCE;

EID: 0033017934     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00035-1     Document Type: Article

References (31)

1. Abad-Zapatero C., Goldman R., Muchmore S.W.et al. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Protein Sci. 5:1996;640.
2. Bairoch A., Apweiler R. The SWISS-PROT protein sequence data bank and its supplement TrEMBL. Nucleic Acids Res. 25:1997;31.
3. Bjerknes R. Flow cytometric assay for combined measurement of phagocytosis and intracellular killing of Candida albicans. J. Immunol. Methods. 72:1984;229.
4. Borg M., Watters D., Reich B., Rüchel R. Production and characterization of monoclonal antibodies against secretory proteinase of Candida albicans CBS 2730. Zentralbl. Bakteriol. Mikrobiol. Hyg. A. 268:1988;62.
5. Cutfield S.M., Dodson E.J., Anderson B.F., Moody P.C., Marshall C.J., Sullivan P.A., Cutfield J.F. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure. 3:1995;1261.
6. Cutler J.E. Putative virulence factors of Candida albicans. Annu. Rev. Microbiol. 45:1991;187.
7. Dorsey B.D., Levin R.B., McDaniel S.L.et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:1994;3443.
8. D'Souza S.E., Ginsberg M.H., Plow E.F. Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem. Sci. 16:1991;246.
9. Fallon K., Bausch K., Noonan J., Huguenel E., Tamburini P. Role of aspartic proteases in disseminated Candida albicans infection in mice. Infect. Immun. 65:1997;551.
10. Flexner C. HIV-protease inhibitors. N. Engl. J. Med. 338:1998;1281.
11. Hoetelmans R.M., Meenhorst P.L., Mulder J.W., Burger D.M., Koks C.H., Beijnen J.H. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm. World Sci. 19:1997;159.
12. Hood S., Bonington A., Evans J., Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS. 12:1998;447.
13. Jahn B., Martin E., Stueben A., Bhakdi S. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J. Clin. Microbiol. 33:1995;661.
14. Klein R.S., Harris C.A., Small C.B., Moll B., Lesser M., Friedland G.H. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:1984;354.
15. Kohl N.E., Emini E.A., Schleif W.A.et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA. 85:1988;4686.
16. Lerner C.G., Goldman R.C. Stimuli that induce production of Candida albicans extracellular aspartyl proteinase. J. Gen. Microbiol. 139:1993;1643.
17. Macdonald F., Odds F.C. Inducible proteinase of Candida albicans in diagnostic serology and in the pathogenesis of systemic candidosis. J. Med. Microbiol. 13:1980;423.
18. Ollert M.W., Wende C., Gorlich M., McMullan-Vogel C.G., Borg-von Zepelin M., Vogel C.W., Korting H.C. Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J. Clin. Microbiol. 33:1995;2543.
19. Powderly W.G., Landay A., Lederman M.M. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA. 280:1998;72.
20. Rizzieri D.A., Liu J., Traweek S.T., Miralles G.D. Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor. Lancet. 349:1997;775.
21. Rüchel R., Ritter B., Schaffrinski M. Modulation of experimental systemic murine candidosis by intravenous pepstatin. Int. J. Med. Microbiol. 273:1990;391.
22. Samaranayake L.P., Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J. Oral Pathol. Med. 18:1989;554.
23. Seelmeier S., Schmidt H., Turk V., von der Helm K. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc. Natl. Acad. Sci. USA. 85:1988;6612.
24. Sepkowitz K.A. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet. 351:1998;228.
25. Shao W., Everitt L., Manchester M., Loeb D.D., Hutchison C.A., Swanstrom R. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc. Natl. Acad. Sci. USA. 94:1997;2243.
26. Stoiber H., Ebenbichler C., Schneider R., Janatova J., Dierich M.P. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS. 9:1995;19.
27. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:1994;4673.
28. Tsuobi R., Kurita Y., Negi M., Ogawa H. A specific inhibitor of keratinolytic proteinase from Candida albicans could inhibit the cell growth of C. albicans. J. Invest. Dermatol. 85:1985;438.
29. Wade, J.C., 1993. Candidiasis - Pathogenesis, Diagnosis and Treatment. Raven Press, New York, p. 85.
30. White T.C., Agabian N. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J. Bacteriol. 177:1995;5215.
31. Zingman B.S. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N. Engl. J. Med. 334:1996;1674-1675.